(firstQuint)Therapeutic Hepatitis B Vaccine (Synthesized Peptide PA-44) Joint Entecavir in Treating Chronic Hepatitis B Patients.

 Eligible subjects are enrolled and assigned into 2 groups randomly with a 1:1 ratio: 1.

 Therapeutic HBV vaccine Joint Entecavir group:Inject mu PA-44 9001/2g at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 + Oral intake entecavir 0.

5mg per day ; 2.

 Empty liposome Joint Entecavir group:Inject empty liposome 9001/2g at week 0, 3, 6, 9, 12, 15, 18, 21, 24, 28, 32, 36, 40, 44, 48 + Oral intake entecavir 0.

5mg per day.

 The study cycle consists of screening and enrollment period (week -4~0), treatment and follow-up period (week 0-96).

.

 Therapeutic Hepatitis B Vaccine (Synthesized Peptide PA-44) Joint Entecavir in Treating Chronic Hepatitis B Patients@highlight

The purpose is to evaluate efficacy and safety of therapeutic hepatitis B virus (HBV) vaccine (synthesized peptide) Joint entecavir treatment in chronic hepatitis B patients.

